Multi-infarct dementia
Multi-infarct dementia is a dementia syndrome caused by cerebral arteriosclerosis affecting the blood supply to the brain, especially recurrent cerebrovascular accidents. Microemboli or ischemia of sclerotic plaques in the external cerebral arteries (carotid arteries or conical basilar arteries) cause scattered small infarcts in the center of the cerebral white matter, hence the name multi-infarct dementia. Multi-infarct dementia usually develops in middle-aged and elderly people, with slightly more men than women. The course of the disease usually develops in a step-by-step manner, often accompanied by localized neurological signs.
-
Site of disease:
Brain -
Infectious :
Not contagious -
Frequent population:
Elderly -
Related symptoms:
Headache dizziness pontine infarction memory impairment headache -
Concurrent disease:
Related Drugs
Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Manufacturer:
Shaanxi Kaiyuan Pharmaceutical Co., Ltd.
Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Manufacturer:
Shanghai Huayuan Pharmaceutical (Ningxia) Shasai Pharmaceutical Co., Ltd.
Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Manufacturer:
Hebei Zhitong Biopharmaceutical Co., Ltd.
Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Manufacturer:
Guangdong Sunho Pharmaceutical Co., Ltd.
Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Manufacturer:
Shanxi Kangbao Biological Product Co., Ltd.
Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Cerebroprotein Hydrolysate Injection
Indication: -Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.
Manufacturer:
Shaanxi Bosen Biological Pharmaceutical Group Co., Ltd.